Developing a drug discovery pipeline can create tremendous opportunities for a startup, but it can also be daunting with many pitfalls. Come to the Atomwise breakfast seminar during the JP Morgan Healthcare Conference to learn from a panel of experienced entrepreneurs, investors, and drug discovery experts as they provide startup-tailored advice on resources, new technologies, fundraising, and pathways to success.
Space is limited - apply for your spot today!
Jon joined Roivant in 2016 and leads a team dedicated to identification of new opportunities across several therapeutic areas, including immunology and oncology. Prior to Roivant, he spent several years as a biotechnology analyst at an investment firm and obtained a medical degree from Columbia University.
Dr. Mochly-Rosen founded three biotech companies, including KAI Pharmaceuticals. Her experience translating basic research to drug development efforts led her to found SPARK, Stanford’s translational research program. In its 13th year, SPARK has a 60% success rate each year, as measured by licensed projects to excising companies (14) or startups (40) and/or conducting clinical studies (38), addressing local and global health care needs. The SPARK model has been adopted in 70 institutes on all continents and Mochly-Rosen serves as President and Founder of the SPARK GLOBAL organization.Jon joined Roivant in 2016 and leads a team dedicated to identification of new opportunities across several therapeutic areas, including immunology and oncology. Prior to Roivant, he spent several years as a biotechnology analyst at an investment firm and obtained a medical degree from Columbia University.
Dr. Woda is an experienced biotechnology leader with expertise in translating biologics from preclinical to clinical programs. Dr. Woda worked for 12 years at multiple biotechnology companies, leading technologies through product development towards pharmaceutically acceptable therapeutics. As Director of Translational Research at Juventas, Dr. Woda led all aspects of translational research, including preclinical development, developing GMP manufacturing processes, leading to the successful submission of an IND and approval for a Phase II clinical study of a novel gene therapy product. As Senior Director of Research and Development at BioMotiv, Dr. Woda co-leads a business unit focused on identification and in licensing of novel discoveries and early product development.
